BCRX, US09058V1035

BioCryst stock: CEO sees 2026 revenue near guidance top

Published on 11/20/2026 at 22:46 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
BioCryst stock is supported by an upper-end 2026 revenue outlook and continued ORLADEYO growth. Navenibart data are due in Q3 2027.

Growth, Competition and Pipeline

  • BioCryst expects ORLADEYO revenue to approach the upper end of its 2026 outlook.
  • Management sees pediatric demand ahead of expectations but expects market-share growth to level off as competition increases.
  • Pivotal navenibart data are expected in the third quarter of 2027.
BCRX, US09058V1035, Illustration mit AI erstellt.

At a Jefferies conference, BioCryst Pharmaceuticals CEO Charlie Gayer said the company expects ORLADEYO revenue to approach the upper end of its 2026 outlook. MarketBeat reported the remarks on Friday, November 20.

BioCryst's ORLADEYO guidance is USD 625 million to USD 645 million. Gayer said more than 1,600 U.S. patients are taking the oral hereditary angioedema treatment, while more than 1,500 clinicians have prescribed it this year. The company is adding more than 60 prescribers per quarter.

ORLADEYO Growth Faces Competition

Management expects ORLADEYO's share of treated hereditary angioedema patients to rise from roughly 22% to 23% into the mid-20% range before leveling off. Gayer pointed to treatment persistence and effectiveness, while acknowledging that additional oral competitors could limit longer-term expansion.

Early uptake of ORLADEYO pellets for children aged 2 to 11 has exceeded expectations, according to the report. BioCryst has identified about 500 pediatric patients in claims data and estimates the potential population could be closer to 1,200.

Navenibart Adds Pipeline Potential

BioCryst expects pivotal data for investigational navenibart in the third quarter of 2027. The study is expected to include six-month and 12-month results. The company plans to use its existing 40-person sales force if the treatment reaches the market.

Management also expects an update in the coming weeks on its investigational Netherton syndrome treatment. BioCryst is assessing additional clinical-stage rare-disease assets as it seeks to broaden its pipeline.

BioCryst stock traded at 6.57 euros on Lang & Schwarz at 22:45 CET on Friday, November 20.

BioCryst Pharmaceuticals, Inc.

  • ISIN: US09058V1035
  • Ticker: BCRX
  • Primary listing: Nasdaq
  • Lang & Schwarz quote: 6.57 euros on November 20, 2026, at 22:45 CET

The broader U.S. market environment is represented by the S&P 500.

More news and analyses on BioCryst Pharmaceuticals stock

Disclaimer...
en | US09058V1035 | BCRX | boerse | 70541181 | bgmi